Lantern Pharma Inc - Asset Resilience Ratio
Lantern Pharma Inc (LTRN) has an Asset Resilience Ratio of 8.15% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Lantern Pharma Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Lantern Pharma Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Lantern Pharma Inc total assets.
Liquid Assets Composition Over Time
This chart breaks down Lantern Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Lantern Pharma Inc (LTRN) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $701.09K | 8.15% |
| Total Liquid Assets | $701.09K | 8.15% |
Asset Resilience Insights
- Limited Liquidity: Lantern Pharma Inc maintains only 8.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lantern Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Lantern Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Lantern Pharma Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Lantern Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.62% | $5.70 Million | $11.04 Million | -12.91pp |
| 2024-12-31 | 64.53% | $16.50 Million | $25.57 Million | +20.17pp |
| 2023-12-31 | 44.37% | $19.36 Million | $43.65 Million | +13.78pp |
| 2022-12-31 | 30.58% | $17.99 Million | $58.84 Million | +4.62pp |
| 2021-12-31 | 25.96% | $19.20 Million | $73.95 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $20.36 Million | -- |
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor,… Read more